We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Press & Announcements

Organogenesis Secures $25M Credit Facility from Silicon Valley Bank

CANTON, Mass. ‐ April 10, 2017 /PRNewswire/ Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, has entered into a revolving line of credit agreement with Silicon Valley Bank (SVB), the bank of the world's most innovative companies and their investors. This agreement provides $25 million of new capital to the company to be used for working capital and general corporate purposes.

"The people of Silicon Valley Bank are not only excellent bankers, but what sets them apart is they also understand business. We at Organogenesis are looking forward to building a strong, long-term relationship," said Tim Cunningham, Chief Financial Officer of Organogenesis Inc.

"Organogenesis is a pioneer in the field of regenerative medicine," said Kevin Longo, Director, Northeast Head of Medical Device and Digital Health, Silicon Valley Bank. "We're pleased to work with the Organogenesis team to provide the best financing, connections and global services they need to meet their corporate objectives."

About Organogenesis

Originally founded as a spin-off from technology developed at MIT in 1985, Massachusetts-based Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products for advanced wound care, orthopedics and spine. Organogenesis' versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

About Silicon Valley Bank

For more than 30 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators.

The Life Science and Healthcare Division of Silicon Valley Bank delivers specialized solutions and market expertise in the areas of biopharma, medical device, tools and diagnostics, digital health and healthcare services, with a focus on helping companies move their bold ideas forward, fast. Learn more at svb.com/life-sciences-healthcare/.

©2017 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).

« Back to Press Releases and Announcements